Tags

Type your tag names separated by a space and hit enter

Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis: Evaluation of Clinical and Magnetic Resonance Imaging Outcomes in a Monocentric Cohort.
Medicine (Baltimore). 2015 Jul; 94(30):e1170.M

Abstract

The primary aim of the study was to evaluate the long-term effectiveness of adalimumab (ADA) in a cohort of non-radiographic axial spondyloarthritis (nr-axSpA), and the secondary aims were to identify predictive factors of response and evaluate radiological progression.We evaluated 37 patients (male/female: 12/25; mean age 49 ± 14; mean disease duration: 6.3 ± 5.8) with active nr-axSpA (Assessment of SpondyloArthritis International Society criteria), despite the treatment with ≥1 nonsteroidal anti-inflammatory drug for at least 3 months, initiating the treatment with ADA 40 mg every other week. Patients were treated for 24 months, and evaluated at baseline, 6, 12, and 24 months. Outcome measures included Ankylosing Spondylitis Disease Activity Score, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and Bath Ankylosing Spondylitis Functional Index. Radiograph of the spine and sacroiliac joints and magnetic resonance of the sacroiliac joints were performed at baseline and according to the standard of assessment for the disease.The proportion of patients that achieved a BASDAI50 response at 6, 12 and 24 months was 51.3%, 70.3%, and 76.8%, respectively. Treatment was well tolerated with no unexpected adverse events and/or serious adverse events. All patients remained on treatment for 2 years, with a good compliance. We did not identify any predictive factor of response to therapy. Moreover, modified Stoke Ankylosing Spondylitis Spine Score and Spondyloarthritis Research Consortium of Canada scores showed a trend of improvement during the study period.ADA was effective on clinical and radiological outcomes at 2-year follow-up; thus, early treatment with ADA may prevent radiographic damage and be associated with low disease activity or remission. Moreover, data from this cohort study have confirmed safety and tolerability profile of ADA in nr-axSpA in the long term.

Authors+Show Affiliations

From the Rheumatology Unit (LC, MF, BF, AV, MGB, MG), Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena; Rheumatology Unit (RT), Department of Clinical and Experimental Medicine, University of Pisa, Pisa; Rheumatology Research Unit (LC), Department of Clinical and Experimental Medicine, University Federico II, Naples; Rheumatology Unit (FC), Department of Medicine DIMED, University of Padua, Padua; Neuroradiology Unit (GLC), S. Donato Hospital, Cardiovascular and Neurologic Department, Arezzo; Radiology Unit (GF), S. Donato Hospital, Department of Diagnostic and Clinical Pathology, Arezzo; and Rheumatology Unit (LS), Department of Internal Medicine, Arezzo, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Observational Study

Language

eng

PubMed ID

26222847

Citation

Cantarini, Luca, et al. "Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis: Evaluation of Clinical and Magnetic Resonance Imaging Outcomes in a Monocentric Cohort." Medicine, vol. 94, no. 30, 2015, pp. e1170.
Cantarini L, Fabbroni M, Talarico R, et al. Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis: Evaluation of Clinical and Magnetic Resonance Imaging Outcomes in a Monocentric Cohort. Medicine (Baltimore). 2015;94(30):e1170.
Cantarini, L., Fabbroni, M., Talarico, R., Costa, L., Caso, F., Cuneo, G. L., Frediani, B., Faralli, G., Vitale, A., Brizi, M. G., Sabadini, L., & Galeazzi, M. (2015). Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis: Evaluation of Clinical and Magnetic Resonance Imaging Outcomes in a Monocentric Cohort. Medicine, 94(30), e1170. https://doi.org/10.1097/MD.0000000000001170
Cantarini L, et al. Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis: Evaluation of Clinical and Magnetic Resonance Imaging Outcomes in a Monocentric Cohort. Medicine (Baltimore). 2015;94(30):e1170. PubMed PMID: 26222847.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis: Evaluation of Clinical and Magnetic Resonance Imaging Outcomes in a Monocentric Cohort. AU - Cantarini,Luca, AU - Fabbroni,Marta, AU - Talarico,Rosaria, AU - Costa,Luisa, AU - Caso,Francesco, AU - Cuneo,Gian Luca, AU - Frediani,Bruno, AU - Faralli,Gabriele, AU - Vitale,Antonio, AU - Brizi,Maria Giuseppina, AU - Sabadini,Luciano, AU - Galeazzi,Mauro, PY - 2015/7/30/entrez PY - 2015/7/30/pubmed PY - 2015/10/21/medline SP - e1170 EP - e1170 JF - Medicine JO - Medicine (Baltimore) VL - 94 IS - 30 N2 - The primary aim of the study was to evaluate the long-term effectiveness of adalimumab (ADA) in a cohort of non-radiographic axial spondyloarthritis (nr-axSpA), and the secondary aims were to identify predictive factors of response and evaluate radiological progression.We evaluated 37 patients (male/female: 12/25; mean age 49 ± 14; mean disease duration: 6.3 ± 5.8) with active nr-axSpA (Assessment of SpondyloArthritis International Society criteria), despite the treatment with ≥1 nonsteroidal anti-inflammatory drug for at least 3 months, initiating the treatment with ADA 40 mg every other week. Patients were treated for 24 months, and evaluated at baseline, 6, 12, and 24 months. Outcome measures included Ankylosing Spondylitis Disease Activity Score, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and Bath Ankylosing Spondylitis Functional Index. Radiograph of the spine and sacroiliac joints and magnetic resonance of the sacroiliac joints were performed at baseline and according to the standard of assessment for the disease.The proportion of patients that achieved a BASDAI50 response at 6, 12 and 24 months was 51.3%, 70.3%, and 76.8%, respectively. Treatment was well tolerated with no unexpected adverse events and/or serious adverse events. All patients remained on treatment for 2 years, with a good compliance. We did not identify any predictive factor of response to therapy. Moreover, modified Stoke Ankylosing Spondylitis Spine Score and Spondyloarthritis Research Consortium of Canada scores showed a trend of improvement during the study period.ADA was effective on clinical and radiological outcomes at 2-year follow-up; thus, early treatment with ADA may prevent radiographic damage and be associated with low disease activity or remission. Moreover, data from this cohort study have confirmed safety and tolerability profile of ADA in nr-axSpA in the long term. SN - 1536-5964 UR - https://www.unboundmedicine.com/medline/citation/26222847/Effectiveness_of_Adalimumab_in_Non_radiographic_Axial_Spondyloarthritis:_Evaluation_of_Clinical_and_Magnetic_Resonance_Imaging_Outcomes_in_a_Monocentric_Cohort_ L2 - http://dx.doi.org/10.1097/MD.0000000000001170 DB - PRIME DP - Unbound Medicine ER -